How does Offspring handle drug target validation?

Our entire philosophy for target validation is built to move beyond simple binding assays and provide the deep, contextual data needed for a confident Go/No-Go decision. We operate under the philosophy that predicting clinical efficacy preclinically requires a holistic view of the target in its native environment: human disease tissue.

While a standard lab might confirm if a target is present, we focus on providing Context. We ask more than simply "is it there?". We ask "is it accessible, is it active, and is it in a position to be drugged?" To do this, we employ a multi-faceted approach to target validation for clinical trials.

Our workflow integrate tissue staining with Single and -Multiplex IHC, chromogenic or fluorescence in situ hybridization (CISH), and isPLA service to characterize your target's expression at both the protein and mRNA level. This is combined with our AI-assisted quantitative image analysis (digital pathology services) to map the distribution and regulation of your target within the specific disease architecture (e.g., Tumor vs. Stroma). This comprehensive approach provides deep confidence that your drug can reach and modulate its target in a way that has the potential to alter the course of the disease with acceptable off-target safety risks.

This systematic approach is designed to rigorously de-risk antibody therapeutics by ensuring your target is not only present, but biologically active and accessible in disease-relevant tissues.